Genetic Mutation Influences Iron Deficiency in Crohn's Disease Patients
A groundbreaking study reveals how genetic mutations in PTPN2 impair iron absorption, leading to anemia in Crohn's disease patients, paving the way for personalized therapies.
Recent research from the University of California, Riverside School of Medicine has uncovered a significant link between a genetic mutation and the severity of iron deficiency in individuals with Crohn's disease, a common form of inflammatory bowel disease (IBD). This discovery sheds light on why some patients experience persistent anemia despite receiving standard iron supplementation.
The study focused on a loss-of-function mutation in the PTPN2 gene, which plays a crucial role in regulating iron levels in the body. Researchers analyzed serum samples from IBD patients and found that carriers of this mutation, present in approximately 14-16% of the general population and 19-20% of IBD patients, exhibited disrupted iron-related blood proteins. This disruption impairs the body's ability to absorb and maintain adequate iron levels, leading to anemia.
Further experiments involving deletion of the PTPN2 gene in mice demonstrated that these animals developed anemia and showed reduced capacity to absorb iron from their diet. This was linked to decreased levels of key iron-absorbing proteins in the intestinal epithelial cells, which are responsible for nutrient uptake. The findings suggest that genetic variants like those in PTPN2 can directly interfere with iron absorption, contributing to persistent anemia in Crohn's disease patients.
"Understanding the genetic factors affecting iron handling opens new possibilities for targeted treatments," explained Dr. Declan McCole, the study’s lead author. "Patients with these genetic variants may benefit more from intravenous iron therapy instead of oral supplements, which are often ineffective in this group."
This research not only advances our understanding of the systemic complications associated with Crohn's disease but also points toward personalized treatment approaches—especially for patients resistant to conventional iron therapy. The study is published in the International Journal of Molecular Sciences and highlights the importance of considering genetic factors in managing Crohn's disease-related anemia.
Source: MedicalXpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Most Patients with Chronic Pain Stop Using Medical Cannabis Within a Year
Over 50% of patients prescribed medical cannabis for chronic pain discontinue its use within a year, highlighting the need for personalized pain management strategies and further research.
Revolutionizing Skin Cancer Detection with AI: A New Tool for Doctors
A new AI system called PanDerm enhances skin cancer detection by analyzing multiple skin images simultaneously, improving accuracy and supporting clinicians in early diagnosis.
International Study Confirms Effectiveness of Selumetinib for Adults with Neurofibromatosis Type 1
A groundbreaking international study confirms that selumetinib effectively reduces tumor size and pain in adults with neurofibromatosis type 1, opening new treatment avenues for this rare genetic disorder.
New Study Confirms Medicaid Expansion Saves Lives in Low-Income Populations
A large-scale study finds Medicaid expansion has significantly decreased mortality among low-income adults, saving thousands of lives since 2010. The research highlights the importance of healthcare policy in improving survival rates.